Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 3
2007 2
2008 2
2010 4
2011 1
2012 6
2013 3
2014 3
2015 3
2016 7
2017 1
2018 9
2019 14
2020 11
2021 16
2022 16
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.
Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C. Boustani J, et al. Among authors: adotevi o. Int J Radiat Biol. 2024 Mar 20:1-10. doi: 10.1080/09553002.2024.2331115. Online ahead of print. Int J Radiat Biol. 2024. PMID: 38506658
THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1.
Giraud J, Chalopin D, Ramel E, Boyer T, Zouine A, Derieppe MA, Larmonier N, Adotevi O, Le Bail B, Blanc JF, Laurent C, Chiche L, Derive M, Nikolski M, Saleh M. Giraud J, et al. Among authors: adotevi o. Cell Rep. 2024 Feb 27;43(2):113773. doi: 10.1016/j.celrep.2024.113773. Epub 2024 Feb 12. Cell Rep. 2024. PMID: 38350444 Free article.
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. Thibaudin M, et al. Among authors: adotevi o. Nat Med. 2023 Aug;29(8):2087-2098. doi: 10.1038/s41591-023-02497-z. Epub 2023 Aug 10. Nat Med. 2023. PMID: 37563240 Free PMC article. Clinical Trial.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. Among authors: adotevi o. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.
Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R. Dalens L, et al. Among authors: adotevi o. Mol Cancer. 2023 Jul 29;22(1):120. doi: 10.1186/s12943-023-01829-4. Mol Cancer. 2023. PMID: 37516818 Free PMC article.
Chemotherapy to potentiate the radiation-induced immune response.
Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O. Lecoester B, et al. Among authors: adotevi o. Int Rev Cell Mol Biol. 2023;376:143-173. doi: 10.1016/bs.ircmb.2023.01.004. Epub 2023 Feb 11. Int Rev Cell Mol Biol. 2023. PMID: 36997268 Review.
103 results